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THE pathogenesis of brain inflammation and damage by
human immunodeficiency virus (HIV) infection is un-
clear. Because blood-brain barrier damage and impaired
cerebral perfusion are common features of HIV-1 infec-
tion, we evaluated the role of tumour necrosis factor-z
(TNF-) and interleukin-lfl (IL-lfl) in mediating disrup-
tion of the blood-brain barrier. Levels of TNF-0 were
more elevated in cerebrospinal fluid (CSF) than in serum
of HIV-1 infected patients and were mainly detected in
those patients who had neurologic involvement. Intrathe-
cal TNF- levels correlated with signs of blood-brain
barrier damage, manifested by high CSF to serum albumin
quotient, and with the degree of barrier impairment. In
contrast, intrathecal IL-lfl levels did not correlate with
blood-brain barrier damage in HIV-1 infected patients.
TNF- seems to be related to active neural inflammation
and to blood-brain barrier damage. The proinflammatory
effects of TNF- in the nervous system are dissociated
from those of IL-lfl.
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Introduction
Neurological complications are a very significant
feature of HIV infection at all stages ranging from
HIV seropositivity through to acquired immune
deficiency syndrome (AIDS)-related complex and
the full-blown AIDS. About 10% of patients with
HIV infection present neurologically,
2 while
approximately 70% of patients with AIDS have
some evidence of neurologic involvement and this
figure may extend to 80% if pathological data are
also taken into consideration.
One of the most important neurologic complica-
tions is an HIV encephalitis, also known as
AIDS--dementia complex, which is caused by a
direct HIV infection within the brain.
3 However,
the precise pathogenesis of brain inflammation and
injury has not been clearly defined and although
HIV has been demonstrated within macrophages
and multinucleate giant cells,
4 its localization within
glial cells and neurons has not been demonstrated
convincingly. The amount of virus detected in some
brain lesions is not proportionate to the degree of
pathologic damage, and some brain regions with
significant damage (e.g. spinal cord) contain little
or no HIV. Similarly, humorally mediated immune
mechanisms are not significantly involved in the
pathogenesis of CNS inflammation or injury,
(C) 1992 Rapid Communications of Oxford ktd
It is therefore likely that indirect mechanisms,
such as the release of cytokines, may play an
important role in mediating brain inflammation in
HIV infection. Indeed there is now increasing
evidence that tumour necrosis factor- (TNF-),
which is a central mediator of inflammation, plays
a crucial role in the development of AIDS.
6 TNF-z
enhances the replication of HIV and induces the
expression of a wide array of inflammatory
cytokines. Moreover, TNF- selectively kills
HIV-infected cells, probably through a direct
cytotoxic effect, and is currently implicated in the
pathogenesis of most clinical and pathologic
features of AIDS.6
Another important pathologic feature that may
contribute to brain damage in HIV infection is the
impairment of the blood-brain barrier. The
detection of viral antigen in cerebral endothelial
cells4 has fuelled speculation that viral entry into
the central nervous system (CNS) may be through
the blood-brain barrier.
7 It follows that HIV
infection of endothelial cells may alter the integrity
of the blood-brain barrier, thereby augmenting
neurologic dysfunction.
6 Indeed several invest-
igators have reported a significant impairment of
the blood-brain barrier in HIV brain inflammation,
which ranged from 27% in the early infection
8 to
79% in more advanced stages.
9 In addition, changes
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in cerebral perfusion occur early in the course of
HIV infection,
1 and HIV seropositive patients
appear to be at increased risk of cerebral ischaemia
and infarction. 11’12 However, the nature and
mechanisms involved in HIV-related damage to
cerebral endothelial cells and the blood-brain
barrier are presently not well understood.
There is considerable evidence that TNF-o
induces inflammatory changes on human cerebral
endothelial cells. Effects of TNF-o that are relevant
to HIV infection include modulation of endothelial
cell functions, 13’14 resulting in endothelial damage,
and an increase in vascular endothelial permeability
leading to vascular leak syndrome
is and impaired
cerebral perfusion. It is therefore likely that TNF-o
induced cerebrovascular disturbance may lead to
brain damage in HIV infected patients. Some of the
proinflammatory effects of TNF-o were reported to
be influenced by interleukin-lfl (IL-1fl).16 Thus, the
aim of this study was to analyse the in vivo
relationship of TNF-o and IL-lfl to impairment of
blood-brain barriers in patients with HIV in-
fections.
Patients and Methods
Patients: Paired CSF and serum samples were
obtained from 31 HIV type-1 (HIV-1) seropositive
patients (25 males, six females). Their ages ranged
from 18 to 43 years (median age of 29.1 years).
Nineteen patients were intravenous drug abusers,
two had a drug-abusing partner, seven were
homosexual (including one who was also a drug
abuser), two were haemophiliacs, and one patient
had received a blood transfusion.
Patients were classified according to the Walter
Reed classification7 (Table 1). Group IV C1
patients who had opportunistic infections of CNS
included cerebral toxoplasmosis (five patients),
cryptococcal meningitis (three patients) and tu-
berculous meningitis (two patients). Group IV C1
patients who had opportunistic infections outside
the CNS included Pneumocystis carinii pneumonia
Table 1. Summary of the clinical features of 31 HIV-1
seropositive patients included in the study
Group No. of Clinical features
patients
Group III
Group IV
Subgroup A
Subgroup B
Subgroup C1
Subgroup D
3 Persistent generalized
lymphadenopathy
3 Constitutional disease
4 Neurological manifestations
10 Secondary infections within the
CNS
9 Secondary infections outside the
CNS
2 Secondary cancers
CNS denotes central nervous system.
(five patients) and refractory pharyngoesophageal
candidiasis (four patients). Neurosyphilis, fre-
quently associated with HIV infection, was ruled
out in all patients by fluorescent treponemal
antibody absorption and treponemal haemoaggluti-
nation tests. Cerebrospinal fluid was obtained by
lumbar puncture and cells were separated by
cytocentrifugation then all samples were filtered
through a 0.45/am disposable sterile filter (Milli-
pore, Watford, UK) to remove contaminating
particulate materials. Samples were frozen in
aliquots at --70C and thawed just before use.
Repeated thawing and refreezing was avoided.
Controls: Control CSF and serum samples were
obtained from two main groups of HIV-1
seronegative patients. The first was the neurologic
control group, which included 20 age- and
sex-matched patients with various non-inflamma-
tory neurologic diseases in whom blood-brain
barrier damage was detected at presentation. They
included six patients with meningioma, four with
craniopharyngioma, three with intracranial arterio-
venous malformation, three with cerebrovascular
diseases, two with benign intracranial hypertension,
and two with obstructive hydrocephalus. The
second group was the disease control, which
consisted of 16 patients with viral meningitis or
rneningoencephalitis.
Assays: All assays were performed in a blinded
fashion on coded sterile samples. Levels of TNF-0
in CSF and homologous serum samples were
determined by a sandwich-type enzyme-linked
immunosorbent assay (ELISA) described pre-
viously.
18 The ELISA had a coefficient of variation
of 4.8% and a lower limit of detection of 2 pg/ml. A
standard curve was run on each ELISA plate using
recombinant human TNF-0 in serial dilutions. A
bioassay utilizing highly sensitive WEHI cells
9 was
employed to verify results obtained by the ELISA.
Levels of IL-lfl in CSF and serum samples were
also measured by a sensitive enzyme immu-
noassay.
2 In our hands the assay had a CV of 5.2%
and a detection limit of 35 pg/ml. The period of
storage of the test samples did not affect the assay
results. Albumin concentrations in CSF and serum
samples were measured by electroimmunoassay.
2
Evaluation of blood-brain barrier: The term blood-brain
barrier describes the overall exclusionary interfaces
that include the epithelium of the choroid plexus,
the endothelial cells of cerebral capillaries, and the
layer of cells lining the arachnoid membrane.
22 The
integrity of the blood-brain barrier was evaluated
by calculating the CSF to serum albumin quotient
23
(Qalb) which is the best chemical indicator of barrier
damage.
2s-25 It is noteworthy, however, that
measurement of Qalb represents an approximation
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to blood-brain barrier breakdown as it commonly
measures breakdown of blood-CSF barrier. The
choroid plexus, in particular, has no significant
blood-tissue barrier function.
Statistics: Non-parametric Wilcoxon sum rank and
Pearson’s correlation matrix tests were used, as
appropriate, for statistical analysis. Relation be-
tween cytokine levels and the degree of barrier
damage was studied by Kruskal-Wallis one-way
analysis of variance. The distribution of TNF-z and
IL-lfl in the study population was evaluated by
confidence intervals for non-parametric data.
26
Results
Cytokine levels" TNF-0c was detected in 18 (58%) CSF
and 15 (48%) serum samples from HIV-1
seropositive patients (Figure 1). TNF-0c was absent
in the serum of three HIV-1 seropositive patients
who had high CSF TNF-0c concentration (54_
14.5 pg/ml). The TNF-0c concentration in CSF
correlated with serum concentration (r-0.73,
p < 0.001)..All the ten subgroup IV C1 patients
with opportunistic CNS infections had high CSF
TNF-0 levels whereas only two of the nine IV C1
patients with opportunistic infections outside the
CNS had high TNF<z in CSF (,p < 0.05). Elevated
CSF levels of TNF-0 were also detected in a patient
from group III, in four patients from group IV B,
and a patient from group IV D.
TNF-0 could not be detected in CSF samples of
patients with viral meningitis and was detected in
the serum of a patient with meningioma and in both
CSF and serum samples from a further four
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FIG. 1. Levels of TNF- in CSF (O) and serum (C)) in the study groups.
Median values and 95% confidence intervals are shown. Shaded area
represents the detection limit of the assay.
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FIG. 2. Levels of IL-qfl in CSF () and serum (O) in the study groups.
Median values and 95% confidence intervals are shown. Shaded area
represents the detection limit of the assay.
neurologic controls (Figure 1: two with stroke and
two with craniopharyngioma).
Interleukin-lfl was detected in seven (23%) CSF
and serum samples from HIV-1 seropositive
patients and in CSF and serum of five neurologic
controls (Figure 2: two with stroke, one with
meningioma and two with craniopharyngioma).
CSF concentrations of IL-lfl in HIV-1 seropositive
patients did not correlate with CSF levels of TNF<z
(r 0.32, p 0.08).
Disruption of the blood-brain barrier: We have already
established
27 that the mean CSF albumin concentra-
tion in normal subjects was 198 mg/1 (range 132 to
295) and the meanQ was 2.1 + 1.6 10 with a
cut-off value of <6. Twenty-two (71%) patients
with HIV infection had abnormally high Qi6
suggestive of barrier impairment. The degree of
disruption to the blood-brain barrier in the study
population was graduated according toQ values,
as described earlier,
24 which produced four separate
groups of barrier condition (Table 2).
Correlation of cytokine levels with barrier impairment:
Intrathecal amounts of TNF-0 and IL-lfl were
determined by calculating the CSF to serum ratios
of these cytokines to correct for passive transuda-
tion across damaged blood-brain barriers. 28’29 In
HIV-1 seropositive patients who had detectable
TNF-0 levels, the CSF to serum ratio of TNF-0
significantly correlated with Qa6 (Figure 3) whereas
HIV-1 seropositive patients who had no detectable
TNF-0 demonstrated no or only mild signs of
blood-brain barrier damage (mean Qalb--5.6 +
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Table 2. Condition of the blood--brain barrier in the study population
Clinical groups Degree of blood-brain barrier damage*
(total number)
No damage Mild Moderate Severe
HIV-1 seropositive patients (31) 9
Viral meningitis (16) 7
Neurologic controls (20) 0
6 6 10
4 4
3 5 12
* According to cerebrospinal fluid/serum albumin quotient x 103 where values <6
indicate no barrier damage, 6 to 10=mild" 10.1 to 15=moderate; and >15.1 to
30 severe barrier damage.
1.02 x 10 -3, p < 0.01). Moreover, the degree of
barrier impairment in HIV-1 seropositive patients
correlated with intrathecal TNF-0 levels (Figure 4).
In contrast, intrathecal levels of IL-lfl in HIV-1
seropositive patients failed to correlate with Qalb
(r 0.17, p 0.12) or with the degree of barrier
damage (Figure 4).
Discussion
In this study high levels of TNF-o were detected
in CSF of HIV-1 seropositive patients who had
neurologic involvement. In addition, TNF- levels
in CSF of these patients were higher than
corresponding serum levels suggesting that TNF-o
is released within the intrathecal compartment. 28’29
This finding is consistent with a previous report,
3
which detected an intrathecal production ofTNF-
in HIV-1 seropositive patients with neurologic
involvement. Gallo et al.,
1 however, failed to detect
TNF-o in AIDS--dementia complex, even when
extensive brain damage was detected. Such
discrepancy may be due to variations in methodo-
logy or differences in patients selection.
The notion that TNF-o is released within the
intrathecal compartment in HIV-1 infection of the
CNS is supported by in vitro studies, which
demonstrated that viral challenge of astrocytes
induces TNF-o release.2 Indeed CSF TNF-o levels
were reported to be more elevated in patients with
HIV-1 encephalopat.hy than in healthy HIV-1
seropositive subjects. This was corroborated by
our results, which showed that CSF levels ofTNF-o
were significantly higher in patients with HIV-1
encephalopathy or opportunistic CNS infections
than in patients with systemic opportunistic
infections without CNS involvement. Intrathecal
production of TNF- may also result from release
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FIG. 3. Correlation of CSF to serum ratio of TNF- with albumin quotient
in 15 HIV-1 seropositive patients who had detectable TNF- in CSF and
serum. Vertical interrupted line represents the cut-off value of albumin
quotient in normal subjects, 0.86, p < 0.001.
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FIG. 4. Correlation of CSF to serum ratios of TNF- and IL-lfl with the
degree of blood-brain barrier damage in 31 HIV-1 seropositive patients.
Values represent means + SEM.TNF- and HIV-1 infection
by macrophages, which are abundant in brain
lesions, as well as by microglial cells.
34
We detected a strong correlation between
intrathecal levels of TNF-o and signs of disruption
of the blood-brain barrier in HIV-1 seropositive
patients with neurologic involvement. Moreover,
TNF-o levels correlated with the degree of barrier
impairment suggesting that this cytokine may be
related to the pathogenesis of barrier damage in
HIV-1 infection. Although our results are not
sufficient to confirm a direct pathogenic effect of
TNF-o on cerebral endothelial cells, a putative
TNF-o-induced disruption of blood-brain barriers
could result from several mechanisms. TNF-o
induces morphologic and structural changes of
endothelial cells through a direct toxic effect. 35 It
also downregulates endothelial cell expression of
thrombomodulin and causes enhanced procoagu-
lant activity that promotes intravascular coagula-
tion and capillary thrombosis.
13 In addition,
leucocytes adherent to endothelial cells are
stimulated by TNF-o to increase biosynthesis and
release of reactive superoxide intermediates and
arachidonic acid metabolites.
36 Further pathological
studies are necessary to elucidate any direct
pathological role of TNF-o in blood-brain barrier
damage in HIV infection.
We detected no relationship between IL-1/g level
and blood-brain barrier damage while such damage
correlated with TNF-o concentrations. Although it
has been suggested that IL-1/J may precipitate
blood-brain barrier damage in experimental ani-
mals,
37 our data suggest that the effects of TNF-o
on human cerebral endothelium can be dissociated
from the presence of IL-1/. In support of our
observation, Saukkonen et al.
38 reported a role of
TNF-o in the generation of inflammation and tissue
damage, while IL-1/ failed to provoke a significant
meningeal response in experimental animals. It
must be emphasized, however, that endothelial
damage should not be considered a result solely of
overproduction of TNF-o, thereby ignoring the
complex interactions between cytokines and other
mediators such as prostaglandins and leukotrienes.
Studies of these and other mediators should provide
a further insight into the pathogenesis of brain
inflammation in HIV infection.
In conclusion, our results provide a molecular
basis for intrathecal inflammatory response in
patients with HIV infection. They further extend
the previously reported effects of TNF-o on the
nervous system in HIV-1 infection and implicate
TNF-o in the blood-brain barrier damage occurring
in this disease. Analysis of the temporal relation
between TNF-o-mediated barrier damage and other
pro-inflammatory effects ofTNF-o on neural tissues
is necessary for a better understanding of
HIV-mediated central nervous system damage.
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